Lakefront Biotherapeutics (LKFT) Invested Capital (2015 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Invested Capital for 11 consecutive years, with $45.0 million the latest figure, recorded in Q4 2025.

• Quarterly Invested Capital fell 59.04% year-over-year to $45.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $45.0 million (down 59.04% YoY) and the FY2025 annual result came in at $45.0 million, down 59.04% from the prior year.
• Invested Capital fell to $45.0 million in Q4 2025 per LKFT's latest filing, from $109.9 million in the prior quarter.
• Over the last five years, Invested Capital for LKFT reached as high as $135.6 million in Q4 2022 and fell as low as $382352.6 in Q2 2021.
• A 5-year average of $79.0 million and a median of $109.9 million in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2021 — Invested Capital plunged 98.77% — and 2022, when it gained 6.77%.
• Year by year, Invested Capital stood at $127.0 million in 2021, then advanced by 6.77% to $135.6 million in 2022, then slipped by 0.51% to $134.9 million in 2023, then declined by 18.56% to $109.9 million in 2024, then sank by 59.04% to $45.0 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $45.0 million, $109.9 million, and $134.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.